• Skip to main content
  • Skip to header right navigation
  • Skip to site footer

Log in
  • Search
    • Search All SAGES Content
    • Search SAGES Guidelines
    • Search the Video Library
    • Search the Image Library
    • Search the Abstracts Archive
www.sages.org

SAGES

Reimagining surgical care for a healthier world

  • Home
    • Search
    • SAGES Home
    • SAGES Foundation Home
  • About
    • Awards
    • Who Is SAGES?
    • Leadership
    • Our Mission
    • Advocacy
    • Committees
      • SAGES Board of Governors
      • Officers and Representatives of the Society
      • Committee Chairs and Co-Chairs
      • Committee Rosters
      • SAGES Past Presidents
  • Meetings
    • SAGES NBT Innovation Weekend
    • SAGES Annual Meeting
      • 2026 Scientific Session Call for Abstracts
      • 2026 Emerging Technology Call for Abstracts
    • CME Claim Form
    • SAGES Past, Present, Future, and Related Meeting Information
    • SAGES Related Meetings & Events Calendar
  • Join SAGES!
    • Membership Application
    • Membership Benefits
    • Membership Types
      • Requirements and Applications for Active Membership in SAGES
      • Requirements and Applications for Affiliate Membership in SAGES
      • Requirements and Applications for Associate Active Membership in SAGES
      • Requirements and Applications for Candidate Membership in SAGES
      • Requirements and Applications for International Membership in SAGES
      • Requirements for Medical Student Membership
    • Member Spotlight
    • Give the Gift of SAGES Membership
  • Patients
    • Join the SAGES Patient Partner Network (PPN)
    • Patient Information Brochures
    • Healthy Sooner – Patient Information for Minimally Invasive Surgery
    • Choosing Wisely – An Initiative of the ABIM Foundation
    • All in the Recovery: Colorectal Cancer Alliance
    • Find A SAGES Surgeon
  • Publications
    • Clinical / Practice / Training Guidelines, Statements, and Standards of Practice
    • Sustainability in Surgical Practice
    • SAGES Stories Podcast
    • Patient Information Brochures
    • Patient Information From SAGES
    • TAVAC – Technology and Value Assessments
    • Surgical Endoscopy and Other Journal Information
    • SAGES Manuals
    • MesSAGES – The SAGES Newsletter
    • COVID-19 Archive
    • Troubleshooting Guides
  • Education
    • Wellness Resources – You Are Not Alone
    • Avoid Opiates After Surgery
    • SAGES Subscription Catalog
    • SAGES TV: Home of SAGES Surgical Videos
    • The SAGES Safe Cholecystectomy Program
    • Masters Program
    • Resident and Fellow Opportunities
      • MIS Fellows Course
      • SAGES Robotics Residents and Fellows Courses
      • SAGES Free Resident Webinar Series
      • Fluorescence-Guided Surgery Course for Fellows
      • Fellows’ Career Development Course
    • SAGES S.M.A.R.T. Enhanced Recovery Program
    • SAGES @ Cine-Med Products
      • SAGES Top 21 Minimally Invasive Procedures Every Practicing Surgeon Should Know
      • SAGES Pearls Step-by-Step
      • SAGES Flexible Endoscopy 101
    • SAGES OR SAFETY Video Activity
  • Opportunities
    • Fellowship Recognition Opportunities
    • SAGES Advanced Flexible Endoscopy Area of Concentrated Training (ACT) SEAL
    • Multi-Society Foregut Fellowship Certification
    • Research Opportunities
    • FLS
    • FES
    • FUSE
    • Jobs Board
    • SAGES Go Global: Global Affairs and Humanitarian Efforts
  • OWLS/FLS
You are here: Home / Abstracts / Clinicopathological Study of Esophagectomized Specimens in Patients with Endoscopic Complete Response Following Chemoradiation in Locally Advanced Esophageal Cancer

Clinicopathological Study of Esophagectomized Specimens in Patients with Endoscopic Complete Response Following Chemoradiation in Locally Advanced Esophageal Cancer

Chadin Tharavej, Patpong Navicharern, Supaut Pungpapong, Krit Kittisin, Suthep Udomsaweangsup. Chulalongkorn University

Background: Upfront chemoradiation (CRT) currently is a standard treatment for locally advanced esophageal cancer. Whether surgery is needed in patients with endoscopic complete response is debatable. We hypothesized that significant number of clinical endoscopic complete response have microscopic residual disease. The aim of this study was to invesitigate clinicopathological outcome of esophagectomy in patients with endoscopic complete response after CRT in locally advanced squamous cell esophageal cancer.

Methods: Patients with locally advanced resectable squamous cell esophageal cancer (T3-T4/N0-1/M0) were included. Patients with significant comorbidity or unfit for surgery were excluded. All patients had planned tranthoracic esophagectomy with 2-field lymphadenectomy 4 months after concurrent 50 Gy of radiotherapy with 2 cycles of 5FU and cis-platin. Endoscopic complete response (enCR) was defined when no mucosal abnormality/negative biopsies were identified. Clinicopathological outcome was examined.

Results: Of 67 patients treated with upfront chemoradiation, 51 had endoscopic complete response and underwent esophagectomy with 2-field lymphadenectomy. Operative mortality was 2%. R-0 resection was 89%. Incidence of pathological complete response (pCR) was 43% and 57% had histologic residual tumor. Five-year survival was 30.5% (50% for pCR and 20% for non-pCR, p=0.04 ). Locoregional recurrence was identified in 24% of enCR with esophageal resection. On histologic examination of 29 esophagectomized specimen with residual viable cancer cell, only 10 (34%) out of 29 specimens had tumor cell presented in mucosal layer.

Conclusion: More than 50% of advanced squamous cell esophageal cancer with clinical endoscopic response after CRT had microscopic residual disease which was R-0 amenable. Viable cancer cell presented in mucosal layer only about a third. Surveillance strategy with intensive endoscopic biopsy would not be able to detect micro residual disease in significant number of esophageal cancer patients with endoscopic complete response following chemoradiation. Planned esophagectomy in endoscopic complete response after CRT was safe and acceptable long term survival. Until an accurate marker for residual disease detection is established, planned esophagectomy, should be an optional treatment in fit patients after CRT for locally advanced squamous cell esophageal cancer.


Presented at the SAGES 2017 Annual Meeting in Houston, TX.

Abstract ID: 77670

Program Number: S026

Presentation Session: Foregut 1

Presentation Type: Podium

13

Share this:

  • Click to share on X (Opens in new window) X
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Mastodon (Opens in new window) Mastodon
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on Bluesky (Opens in new window) Bluesky

Related


sages_adbutler_leaderboard

Hours & Info

11300 West Olympic Blvd, Suite 600
Los Angeles, CA 90064

1-310-437-0544

[email protected]

Monday – Friday
8am to 5pm Pacific Time

Find Us Around the Web!

  • Bluesky
  • X
  • Instagram
  • Facebook
  • YouTube

Copyright © 2025 · SAGES · All Rights Reserved

Important Links

Healthy Sooner: Patient Information

SAGES Guidelines, Statements, & Standards of Practice

SAGES Manuals